Thymidine Kinase Deficiency

Updated: December 19, 2025

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

doxecitine/doxribtimine

Divide the total daily amount into three equal oral doses administered approximately every 6 hours (±2 hours), preferably taken with food.
Administer 260 mg/kg orally daily as an initial dose (130 mg each of doxribtimine and doxecitine)
Administer 520 mg/kg orally daily as intermediate dose (260 mg each of doxribtimine and doxecitine)
Administer 800 mg/kg orally daily as a maintenance dose (400 mg each of doxribtimine and doxecitine)

doxecitine/doxribtimine